AR078950A1 - Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales - Google Patents

Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales

Info

Publication number
AR078950A1
AR078950A1 ARP100104153A ARP100104153A AR078950A1 AR 078950 A1 AR078950 A1 AR 078950A1 AR P100104153 A ARP100104153 A AR P100104153A AR P100104153 A ARP100104153 A AR P100104153A AR 078950 A1 AR078950 A1 AR 078950A1
Authority
AR
Argentina
Prior art keywords
acid
cys
asp
glu
carboxylated
Prior art date
Application number
ARP100104153A
Other languages
English (en)
Spanish (es)
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of AR078950A1 publication Critical patent/AR078950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
ARP100104153A 2009-11-09 2010-11-09 Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales AR078950A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
AR078950A1 true AR078950A1 (es) 2011-12-14

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104153A AR078950A1 (es) 2009-11-09 2010-11-09 Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales

Country Status (26)

Country Link
US (3) US20140179607A9 (cg-RX-API-DMAC7.html)
EP (1) EP2499154B1 (cg-RX-API-DMAC7.html)
JP (1) JP5913115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120115495A (cg-RX-API-DMAC7.html)
CN (1) CN102812038B (cg-RX-API-DMAC7.html)
AR (1) AR078950A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010314866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779482A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012001186A1 (cg-RX-API-DMAC7.html)
CO (1) CO6551683A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120303A (cg-RX-API-DMAC7.html)
EA (1) EA022817B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011962A (cg-RX-API-DMAC7.html)
ES (1) ES2620153T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166435B (cg-RX-API-DMAC7.html)
IL (1) IL219596A0 (cg-RX-API-DMAC7.html)
MX (2) MX350046B (cg-RX-API-DMAC7.html)
NZ (1) NZ599751A (cg-RX-API-DMAC7.html)
PH (1) PH12012500916B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201407403UA (cg-RX-API-DMAC7.html)
TW (1) TWI482626B (cg-RX-API-DMAC7.html)
UA (1) UA114274C2 (cg-RX-API-DMAC7.html)
UY (2) UY33018A (cg-RX-API-DMAC7.html)
WO (1) WO2011057272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201203342B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2012510518A (ja) * 2008-12-02 2012-05-10 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 体液貯留障害を処置するための方法および組成物
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
CA2835624A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX347354B (es) * 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
DE69433564T2 (de) 1993-10-26 2004-12-23 Thomas Jefferson University Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2001080871A2 (de) * 2000-04-22 2001-11-01 Ipf Pharmaceuticals Gmbh Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
SG193801A1 (en) 2008-08-15 2013-10-30 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
CA2779482A1 (en) 2011-05-12
CO6551683A2 (es) 2012-10-31
TWI482626B (zh) 2015-05-01
IL219596A0 (en) 2012-06-28
SG10201407403UA (en) 2014-12-30
PH12012500916B1 (en) 2018-03-23
AU2010314866A1 (en) 2012-05-31
JP2013510182A (ja) 2013-03-21
KR20120115495A (ko) 2012-10-18
UY33017A (es) 2011-06-30
WO2011057272A1 (en) 2011-05-12
EA201290322A1 (ru) 2013-01-30
US20130085107A1 (en) 2013-04-04
MX350046B (es) 2017-08-24
EP2499154A1 (en) 2012-09-19
ES2620153T3 (es) 2017-06-27
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
CL2012001186A1 (es) 2013-07-12
MX2012005368A (es) 2012-06-13
UA114274C2 (uk) 2017-05-25
CN102812038A (zh) 2012-12-05
US8946158B2 (en) 2015-02-03
EA022817B1 (ru) 2016-03-31
US20140024593A1 (en) 2014-01-23
BR112012011730A2 (pt) 2016-03-08
JP5913115B2 (ja) 2016-05-11
TW201116291A (en) 2011-05-16
NZ599751A (en) 2014-08-29
US8507447B2 (en) 2013-08-13
GEP20166435B (en) 2016-02-25
ECSP12011962A (es) 2012-07-31
UY33018A (es) 2011-01-31
ZA201203342B (en) 2013-01-30
CR20120303A (es) 2012-08-08
EP2499154B1 (en) 2016-12-21
PH12012500916A1 (en) 2018-01-29
AU2010314866B2 (en) 2014-10-30
US20140179607A9 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
AR078950A1 (es) Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales
Raizada et al. ACE2: a new target for cardiovascular disease therapeutics
ES2655389T3 (es) Compstatina modificada con esqueleto peptídico y modificaciones c-terminales
MX2019013628A (es) Formulaciones que contienen linaclotida para administracion oral.
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
US10363282B2 (en) Analogs of C5a and methods of using same
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
AU2019398467A1 (en) Transferrin receptor targeting peptides
AU2018205186B2 (en) Angiotensin in treating brain conditions
AR060487A1 (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
CA2697504A1 (en) Salicylanilide modified peptides for use as oral therapeutics
WO2020028439A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
HRP20161560T1 (hr) Varijanta, rekombinantnih proteina beta-glukocerebrozidaze s povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću
RU2013146690A (ru) Циклические пептиды с антинеопластической и антиангионенной активностью
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
CA3073062A1 (en) Tau aggregation peptide inhibitors
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
PH12015502005B1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
CA2912635A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
CN105636645A (zh) 在肌萎缩症中的血管紧张素
CA2940751A1 (en) Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke
Barreto et al. Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice
AU2013215269A1 (en) Beta-arrestin effectors and compositions and methods of use thereof
KR20160065969A (ko) 신규 펩티드 조성물

Legal Events

Date Code Title Description
FB Suspension of granting procedure